Table 3. Correlation of INSR expression with clinicopathological characteristics in BRCA patients.
| Characteristics | INSR | P-value | ||
| Weak | Moderate | Strong | ||
| Statistical significance was calculated by Chi-square test. *P<0.05,***P<0.001,****P<0.0001. INSR: insulin receptor; LNM: lymph node metastasis; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; Ki-67: proliferation index with a cut off value of 14%.
| ||||
| Age (years) | 0.558 | |||
| ≥50 | 56 | 25 | 13 | |
| <50 | 17 | 8 | 7 | |
| Tumor size (cm) | 0.197 | |||
| ≥2 | 60 | 26 | 19 | |
| <2 | 16 | 4 | 1 | |
| LNM status | 5.051E−6**** | |||
| Positive | 15 | 17 | 14 | |
| Negative | 61 | 13 | 6 | |
| Clinical tumor stages | 0.026* | |||
| Ⅰ –Ⅱ | 29 | 20 | 13 | |
| Ⅲ | 46 | 11 | 7 | |
| ER | 2.819E−4*** | |||
| Positive | 3 | 7 | 7 | |
| Negative | 73 | 23 | 13 | |
| PR | 2.818E−6**** | |||
| Positive | 5 | 7 | 11 | |
| Negative | 71 | 23 | 9 | |
| HER2 | 0.319 | |||
| Positive | 4 | 3 | 3 | |
| Negative | 72 | 27 | 17 | |
| Ki-67 | 1.237E−4*** | |||
| High | 53 | 11 | 5 | |
| Low | 23 | 19 | 15 | |